ABBVIE WKN: A1J84E ISIN: US00287Y1091 Forum: Aktien Thema: Hauptdiskussion

Bin ich zu 100% bei Dir 👍🏻

Momentan sehe ich keine bessere Dividendenaktie am Markt.Sehr schönes Diviwachstum mit niedriger Bewertung,starkem Cashflow und payout Ratio unter 50.Dazu starke Pipeline in einem auch zukünftig wichtigem Markt und ein sehr geschliffenes Management 👌

Nächster harter Widerstand wären 80 Dollar

Die 74,50 Dollar sind ne Hürde, könnte kurzfristig nochmal tiefer gehen

Danke euch!! 🤗Ist aber keine Kunst, Abbvie ist auch ohne mich deutlich unterbewertet ✌️

Olli treibt den Kurs nach oben 👍

Der Olli ist ein wandelndes Nachrichtenblatt 👍

Danke für die fortlaufenden News hier!

Citigroup hebt Kursziel auf 90 Dollar

Citi upgrades AbbVie in premarket analyst actionhttps://seekingalpha.com/news/3502015

Auch wenn es heute erstmal bergab geht.. Jim Cramer assesses recent acquisitions in AbbVie and Bristol-Myers Thursday, 19 Sep 2019 | 5:00 PM PT Jim Cramer breaks down large acquisitions that AbbVie and Bristol-Myers recently *** and explains why he's recommending AbbVie as a buy. Their acquisition of Allergan will create a new company churning out $20 billion in free cash flow a year, plus a much needed pipeline. www.cnbc.com/...

AbbVie And Allergan: Huge Debt Levels And Doubtful Growth $ABBVhttps://seekingalpha.com/article/4293484

VENCLEXTA®, a treatment for chronic lymphocytic leukemia (CLL), now reimbursed across Western Canada $ABBVhttps://seekingalpha.com/pr/17643447

Schöne Zusammenfassung für Interessierte, wenn auch in Englisch. Quelle Seeking Alpha AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström’s macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson’s disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; and Calico Life Sciences LLC. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie: The Allergan Merger Is Poised To Be More Accretive Than The Market Realizes $ABBVhttps://seekingalpha.com/article/4293232

Total ist vor allem eine Cashmaschine. Diese Woche Vortrag in den USA was mit der großen Kohle passieren soll. ARP oder höhere Divi durchaus möglich bei Total. Sorry für Off-Topic ✌️